沙库巴曲缬沙坦治疗慢性心力衰竭患者疗效及肝肾功能影响

The Effect of Sacubitril Valsartan on Liver and Kidney Function in Patients with Chronic Heart Failure

目的观察沙库巴曲缬沙坦治疗慢性心力衰竭患者疗效及对肝肾功能的影响。方法选取2021年1月—2021年12月在陕西省铜川市人民医院就诊或住院的慢性心力衰竭患者200例作为研究对象,按照随机数表法分为观察组和对照组,每组100例,对照组给予利尿剂、扩张血管药物、β-受体拮抗剂等治疗,观察组在对照组基础上给予沙库巴曲缬沙坦治疗,对比两组患者治疗总有效率、治疗前后肝肾功能、心功能及治疗后不良反应发生率。结果观察组患者的治疗总有效率高于对照组(P<0.05);治疗前两组患者的谷氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、血清肌酐(Scr)、尿素氮(BUN)水平比较,差异无统计学意义(P>0.05),治疗后两组患者的ALT、AST、SCr、BUN水平均降低,并且治疗后观察组患者以上指标明显低于对照组(P<0.05);治疗前两组患者的N-末端B型利钠肽原(NT-proBNP)水平比较,差异无统计学意义(P>0.05),治疗后两组患者的NT-proBNP水平均降低,并且治疗后观察组患者NT-proBNP水平明显低于对照组(P<0.05);治疗前两组患者的左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)、6 min步行试验(6MWT)水平比较,差异无统计学意义(P>0.05),治疗后两组患者的LVEDD、LVESD水平均降低,LVEF、6MWT水平均升高,并且观察组患者以上指标改善情况优于对照组(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论给予慢性心力衰竭患者沙库巴曲缬沙坦治疗,能提升治疗效果,促进肝肾功能、心功能改善,延缓病情进展,且不会增加不良反应。

Objective To observe the eff ect and infl uence of liver and kidney function of Sacubitril Valsartan in patients of chronic heart failure.Methods 200 patients with chronic heart failure who were treated or hospitalized in Tongchuan People’s Hospital from January 2021 to December 2021 were collected as the subjects of this study.According to the method of random number table,they were divided into observation group and control group,100 patients in each group,both groups were given diuretics,vasodilators,β-Receptor antagonists and other treatments.The observation group was treated with Sacubitril Valsartan on the basis of the above.The total eff ective rate,the liver and kidney functions and cardiac functions before and after treatment,and the incidence of adverse reactions after treatment of the two groups were compared.Results The total eff ective rate of the observation group was higher than that of the control group(P<0.05);there was no signifi cant diff erence in Alt,AST,SCR and BUN levels between the two groups before treatment(P>0.05),after treatment,the Alt,AST,SCR and BUN levels of the two groups were decreased,and after treatment,the above indexes of the observation group were decreased,the range was greater than that of the control group(P<0.05);there was no signifi cant diff erence in NT-proBNP levels between the two groups before treatment(P>0.05),after treatment,NT-proBNP levels in the two groups decreased on average,and after treatment,the decrease in the observation group was greater than that in the control group(P<0.05);there was no signifi cant diff erence in the levels of LVEDD,LVESD,LVEF and 6MWT between the two groups before treatment(P>0.05),after treatment,the levels of LVEDD and LVESD in the two groups decreased,and the levels of LVEF and 6MWT increased on average,the improvement of the above indexes in the observation group was better than that in the control group(P<0.05);there was no signifi cant diff erence in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The treatment of chronic heart failure patients with Sacubitril Valsartan can improve the treatment eff ect,promote the improvement of liver,kidney function and heart function,delay the progress of the disease,and it will not increase the adverse reactions.